Cancer Genetics and Epigenetics 2018, Vol.6, No.2, 13-18
18
Milioli H.H., Tishchenko I., Riveros C., et al, 2017, Basal-like breast cancer molecular profiles, clinical features and survival outcomes, Bmc Medical
Genomics, 10(1): 19
PMid:28351365 PMCid:PMC5370447
Perou C.M., Sorlie T., Eisen M.B., et al, 2000, Molecular portraits of human breast tumours, Nature, 406(6797): 747-752
PMid:10963602
Roberto R., Rosato, Daniel Dávila-González, et al., 2018, Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft
tumors engrafted in humanized mouse models, Breast Cancer Res, 20: 108
PMid:30185216 PMCid:PMC6125882
Shaughnessy J., Osborne C., Pippen J.E., et al., 2011, Iniparibplus chemotherapy in metastatic triple-negative breast cancer, N Engl J Med, 364(3): 205-214
PMid:2120810
Sinha G., 2014, Downfall of iniparib: a PARP inhibitor that doesn’t inhibit PARP after all, J Natl Cancer Inst, 106(1): djt4
PMid:24402426
Wataru G., Shinichiro K., Koji T., et al., 2018, Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy, J
Transl Med, 16: 307
PMid:30413161
Xie T.W., ZhaoQ.F., Fu C.X., et al., 2018, Differentiation of triple-negative breast cancer from other subtypes through whole-tumor histogram analysis on
multiparametric MR imaging, Eur Radiol
PMCid:PMC6230295
Xu Q.Q., Wang C.J., Sun Q., et al., 2017, Triple-negative breast cancer:Molecular subtypes and individual targeted therapies, Chinese journal of cancer
prevention, 24(11): 788-794
